RandomizEd phase II trial of Sunitinib four weeks on and two weeks off versus Two weeks on and One week off in metastatic clear-cell type REnal cell carcinoma: RESTORE trial-Reference-Cited by-同舟云学术

RandomizEd phase II trial of Sunitinib four weeks on and two weeks off versus Two weeks on and One week off in metastatic clear-cell type REnal cell carcinoma: RESTORE trial

Published:2015-11 Issue:11 Volume:26 Page:2300-2305
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Lee J.L.,Kim M.K.,Park I.,Ahn J.-H.,Lee D.H.,Ryoo H.M.,Song C.,Hong B.,Hong J.H.,Ahn H.

Funder

Korea Healthcare Technology R&D Project

Ministry of Health and Welfare, Republic of Korea

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/26/11/2300/16699106/mdv357.pdf

Reference18 articles.

1. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma;Motzer;N Engl J Med,2007

2. Pazopanib versus sunitinib in metastatic renal-cell carcinoma;Motzer;N Engl J Med,2013

3. Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis;Houk;Cancer Chemother Pharmacol,2010

4. The efficacy and safety of sunitinib in Korean patients with advanced renal cell carcinoma: high incidence of toxicity leads to frequent dose reduction;Yoo;Jpn J Clin Oncol,2010

5. Overall survival and updated results from a phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma;Tomita;Jpn J Clin Oncol,2010

Cited by 90 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Anti-VEGF and -PD-1 Combinations in Renal Cell Carcinoma: When Are Treatment Breaks Safe?;European Urology;2024-06

2. A Prospective Cohort Study Exploring the Effect of Lenvatinib Planned Drug Holidays in Treatment of Differentiated Thyroid Cancer;Thyroid®;2024-05-01

3. A Comprehensive Review of Cancer Drug–Induced Cardiotoxicity in Blood Cancer Patients: Current Perspectives and Therapeutic Strategies;Current Treatment Options in Oncology;2024-02-19

4. 2/1 dose schedule of sunitinib is superior than the 4/2 regimen for the first-line therapy of clear cell metastatic renal cell carcinoma – An Indian experience;Indian Journal of Cancer;2023-10

5. Interdisziplinäre Empfehlungen zur Behandlung des fortgeschrittenen Nierenzellkarzinoms;TumorDiagnostik & Therapie;2023-07-31